Dynavax Technologies Total Assets 2010-2022 | DVAX

Dynavax Technologies total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Dynavax Technologies Annual Total Assets
(Millions of US $)
2021 $1,039
2020 $353
2019 $279
2018 $211
2017 $219
2016 $110
2015 $217
2014 $138
2013 $205
2012 $140
2011 $134
2010 $84
2009 $50
Dynavax Technologies Quarterly Total Assets
(Millions of US $)
2022-03-31 $1,009
2021-12-31 $1,039
2021-09-30 $920
2021-06-30 $648
2021-03-31 $490
2020-12-31 $353
2020-09-30 $353
2020-06-30 $329
2020-03-31 $259
2019-12-31 $279
2019-09-30 $301
2019-06-30 $267
2019-03-31 $297
2018-12-31 $211
2018-09-30 $236
2018-06-30 $264
2018-03-31 $295
2017-12-31 $219
2017-09-30 $218
2017-06-30 $152
2017-03-31 $110
2016-12-31 $110
2016-09-30 $139
2016-06-30 $168
2016-03-31 $190
2015-12-31 $217
2015-09-30 $239
2015-06-30 $109
2015-03-31 $112
2014-12-31 $138
2014-09-30 $147
2014-06-30 $173
2014-03-31 $194
2013-12-31 $205
2013-09-30 $92
2013-06-30 $104
2013-03-31 $120
2012-12-31 $140
2012-09-30 $165
2012-06-30 $176
2012-03-31 $121
2011-12-31 $134
2011-09-30 $65
2011-06-30 $74
2011-03-31 $66
2010-12-31 $84
2010-09-30 $62
2010-06-30 $72
2010-03-31 $44
2009-12-31 $50
2009-09-30 $62
2009-06-30 $69
2009-03-31 $78
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.475B $0.439B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00